KIDNEY TRANSPLANT MARKET ANALYSIS

Key Developments

• On 24 April 2024, The National Kidney Registry (NKR) celebrated its 9,000th successful living kidney donor transplant at Hartford Hospital, making it the world's largest kidney paired donation registry. NKR now oversees 25% of all living donor transplants in the US, up from 23% in 2023. They facilitate over 1,000 transplants annually, aided by initiatives like microsites, Donor Connect, and Donor Shield, ensuring support and protection for donors.
• On 8 May 2024, The U.S. Department of Health and Human Services (HHS), via the Centers for Medicare & Medicaid Services (CMS), is launching the Increasing Organ Transplant Access (IOTA) Model to improve kidney transplant access, quality of care, and reduce disparities. The model targets transplant hospitals, requiring a minimum of 11 transplants annually over three years. Participating hospitals must develop health equity plans. The proposed rule can be found in the Federal Register, with standard provisions applicable to model participants starting January 1, 2025.
• In February 2022, Bio-Techne Corporation, global developer, manufacturer and supplier of high-quality reagents, analytical instruments have partnered with Thermo Fisher Scientific, global pharmaceutical and biotechnology company to exclusively develop and commercialize the ExoTRU kidney transplant rejection test from Exosome Diagnostics, a Bio-Techne brand. ExoTRU is a non-invasive urine-based liquid biopsy assay that provides essential allograft health information to aid clinicians in managing kidney transplant patients and optimizing care. The assay has the potential to distinguish between T-cell mediated rejection (TCMR) and antibody mediated rejection (ABMR), crucial for improving patient outcomes.
• In April 2021, Sanofi global healthcare and pharmaceutical company has agreed to merge with Kadmon Holdings, Inc biopharmaceutical company acquiring Rezurock (belumosudil), a first-in-class treatment for chronic graft-versus-host disease (cGVHD). This aligns with Sanofi's strategy to expand its General Medicines core assets.